Zacks Small-Cap Research

August 30, 2013

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

scr.zacks.com

111 North Canal Street, Chicago, IL 60606

Biomerica Inc (BMRA-OTCBB)

BMRA: Look For Revenue Rebound With New China Distribution

Current Recommendation	**Outperform**
Prior Recommendation	N/A
Date of Last Change	01/23/2013
Current Price (08/30/13)	$0.91
Target Price	**$2.50**

OUTLOOK

Biomerica has been profitable over ten of the last eleven quarters, has regularly generated positive cash flow, and maintains a stellar balance sheet. We think it is clear that management and the board lead the company in a way with an eye on increasing shareholder value. We have come across few companies that have been in existence over 40 years, possess all of the positive characteristics of BMRA and yet trade at what we would characterize as an incredibly cheap valuation. We see very little to no downside risk in the share price at this level. We think the cheap valuation may have more to do with BMRA being a nano-cap and suffering from a lack of exposure rather than having anything to do with fundamentals.

SUMMARY DATA

52-Week High	**$1.25**
52-Week Low	**$0.65**
One-Year Return (%)	**23.29**
Beta	**0.94**
Average Daily Volume (sh)	**4,863**
Shares Outstanding (mil)	**7**
Market Capitalization ($mil)	**$7**
Short Interest Ratio (days)	**1.23**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**28**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**6.4**
Earnings Per Share (%)	**57.6**
Dividend (%)	**N/A**
P/E using TTM EPS	**13.0**
P/E using 2014 Estimate	**8.3**
P/E using 2015 Estimate	**6.5**
Zacks Rank	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**Small-Value**
Industry	**Med-Drugs**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Aug)	Q2 (Nov)	Q3 (Feb)	Q4 (May)	Year (May)
2013	1.70 A	1.88 A	1.42 A	1.47 A	6.47 A
2014	1.44 E	1.77 E	1.93 E	2.02 E	7.15 E
2015					8.63 E
2016					10.14 E

Earnings per Share
(EPS is operating earnings before non recurring items)

	Q1 (Aug)	Q2 (Nov)	Q3 (Feb)	Q4 (May)	Year (May)
2013	$0.04 A	$0.03 A	-$0.01 A	$0.01 A	$0.07 A
2014	$0.00 E	$0.02 E	$0.04 E	$0.05 E	$0.11 E
2015					$0.14 E
2016					$0.15 E

Zacks Projected EPS Growth Rate - Next 4 Years % **28**

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW……

Q4 Results: *Change in China Distribution Interrupts Revenue Growth*

Biomerica filed their 10-K for the fiscal quarter and year ending May 31, 2013. For the second straight quarter revenue was below our number with sales in Asia again coming in much softer than anticipated. Management acknowledged revenue in second half of fiscal 2013 was a disappointment but continues to look for this to turn around. The relative weakness in Asian sales appears directly related to a change in distributors. A distribution agreement was consummated with a new distributor in China during fiscal Q4. Biomerica notes that this distributor has indicated that they expect to increase sales to the same levels as that of the prior distributor. As a result of the interruption in Asia (which has accounted for ~40% of total revenue), we now model a contraction in revenue in the first half of fiscal 2014 but for sales to show meaningful growth in the back half of the year, reflecting the expectation that sales to the new distributor begin to ramp up towards legacy levels.

Meanwhile, sales in Europe were very strong in Q4 at $1.0 million, reflecting 48% yoy growth and representing 70% (Europe sales typically account for ~40% of total revenue) of total revenue for the quarter. BMRA noted that increased sales of products not previously purchased in Europe was the reason for the relatively strong European revenue.

Total revenue fell 4.7% yoy (sequentially flat) in Q4 to $1.47 million and was about 19% below our $1.82 million number. Almost the entire miss was a result of lower than modeled ($267k A vs. $889k E) sales in Asia. This was partially offset by very strong sales in Europe ($1,030 A vs. $712k E).

Q4 gross margin of 32.7% was also well below our estimate of 41.5%, likely due to the much lower revenue number. Operating expenses were in-line with our estimates. Q4 net income and EPS were $44k and $0.01 compared to our $254k and $0.03 estimates. For the fiscal year, net income and EPS were $537k and $0.07, compared to $548k and $0.08 in fiscal 2012.

Cash

BMRA exited fiscal 2013 with $2.5 million in cash and equivalents, up slightly from $2.3 million at the end of Q3. Cash used in operating activities was $102k in Q4. For the full year, cash flow from operating activities was an inflow of $1.4 million. BMRA remains debt free and the balance sheet remains very strong. Book value at 5/31/2013 was $5.8 million or $0.78/share compared to $5.5 million or $0.78/share at the end of fiscal 2012.

Maintaining Outlook / Recommendation

We have made some revisions to our model, mostly reflecting the hiccup in revenue as a result in the switch in distribution in China. We look for revenue to return to long-term growth towards the back half of fiscal 2014. BMRA also recently penned a new distribution agreement in Mexico and announced their H.Pylori and Parathyroid Hormone tests were approved for sale in Mexico. The company also expects other new product approvals throughout the current year.

We now look for 2014 revenue and EPS of $7.2 million (+10.5% yoy) and $0.11 and for this to grow to $11.9 million and $0.19 in fiscal 2017. We are maintaining our Outperform rating. Our fundamental outlook remains unchanged and highly positive. We have moved our per share price target from $2.70 to $2.50, reflecting both changes in comparable valuations as well as some slight downward revisions to our model - mostly related to the near-term.

BACKGROUND

For over 40 years Biomerica, Inc. (BMRA) has been involved in the development, manufacturing and marketing of medical diagnostics products for the early detection and monitoring of chronic diseases and medical conditions. Their product line encompasses various diseases and conditions including tests for gastrointestinal/foodborne diseases, infectious diseases, diabetes, women's health, hormone levels and even some esoteric diseases. The company's particular focus is on gastrointestinal/foodborne diseases and diabetes.

The tests are sold into two major market segments, clinical lab and point-of-care (POC). Demand for the clinical lab products mainly comes from hospitals and clinical and research laboratories. The POC segment, which may hold particularly attractive opportunities for growth given recent technological advancements which have significantly improved speed and accuracy of certain rapid tests, includes the over-the-counter retail channel as well as physician offices. Biomerica sells through distributors as well as directly. The majority of Biomerica's revenue is generated from international sales, particularly from Europe and Asia, while domestic sales account for approximately 15% - 20% of total revenue.

Biomerica recently divested the bulk of their internal research and development department in order to focus on a strategy of in-licensing technology and products from other companies, universities and institutions which they expect to result in a greater rate of revenue and earnings growth. The company, with headquarters and administrative offices in Southern California, maintains a portion of their manufacturing facilities in Mexico which helps reduce COGS and operating costs. Since the R&D divestiture in July 2010 BMRA has made meaningful progress in pursuing accelerated growth including the acquisition of several new high potential products as well as consummating additional distribution agreements.

Relative to their financials, revenue grew 24% in fiscal 2012 and was up 6% in 2013. While the first half of fiscal 2013 exhibited strong 19% growth, revenue in the second half contracted by 6%, largely due to a change in distributors in China. The revenue contraction due to the swap in distributors in China is expected to be a short-term issue. Biomerica has been profitable over ten of the last eleven quarters, has regularly generated positive cash flow (from both an operational cash flow and free cash flow standpoint), and maintains a stellar balance sheet. Add to this the fact that executive compensation is relatively meager (possibly the lowest of any company we cover in the med-tech space), a minimal outstanding share count (7.5 million diluted, 7.0 million basic at most recent year-end), and obvious diligence on growing revenue while leveraging their cost base and we think all this is clear evidence that management and the board lead the company in a way with an eye on increasing shareholder value. In our experience, we have come across few companies that have been in existence over 40 years (as BMRA has) and possess all of these positive characteristics yet trade at what we would characterize as an incredibly cheap valuation. As of today's market price BMRA is valued at just 1.1x book value, only 12x trailing EPS, and just 8x our current year EPS estimate.

Given that BMRA trades at roughly book value, has liquid and high quality assets and no debt, and is generating positive cash flow (i.e. - book value is increasing), we see very little to no downside risk in the share price at this level. We think the cheap valuation may have more to do with BMRA being a nano-cap and suffering from a lack of exposure rather than having anything to do with fundamentals. We think the current market value grossly undervalues the company and recommend accumulating the shares up to our $2.50 price target.

PRODUCTS



biomerica.com

Biomerica's diagnostic test kits and components are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations.

The company sells their diagnostic tests worldwide into two major market segments; clinical laboratories and POC. The clinical laboratories tests are enzyme linked immunosorbent assays (ELISA) which are often processed using sophisticated instrumentation at professional and research laboratories. By contrast the POC tests are rapid tests which require minimal handling or special knowledge and can be performed at home or in the physicians office with results typically available within minutes.

Roughly 30% (14) of Biomerica's products are FDA approved for sale in the U.S. In addition to being sold in the U.S., some of these FDA-approved tests are also sold overseas. Of the FDA-approved products, three (Drugs-of-Abuse, Breast Self Exam, and Fecal Occult Blood) are approved for sale through the OTC (retail) channel, three (Rapid Pregnancy, Rapid Ovulation, and Fecal Occult Blood) are CLIA-waived and are used in physicians' offices and the remaining eight are sold to the clinical lab channel.

Similar to the FDA-approved product mix, roughly 60% - 65% of the non-FDA products are sold to the clinical lab channel with the remainder roughly evenly split between physician's office and OTC. The non-FDA cleared clinical lab products can only be sold as analyte specific reagents (ASR) and labeled "for research purposes only" - the distinction being that (among other things) the manufacturer is restricted in the claims that they can make regarding the performance or validation of the products. For clarity, ASR's are a huge part of in-vitro diagnostics (IVD) testing in the U.S. and are widely accepted as scientifically valid. The non-FDA cleared POC tests, however, can not be sold in the U.S. While Biomerica does not disclose revenue by product or customer channel, based on the geographical mix of sales and the fact that the non-FDA cleared POC tests can not be sold in the U.S., we think it's safe to assume that the clinical lab products account for the majority of total revenue. In the U.S., however, the POC products (particularly through the OTC channel) likely account for the majority of domestic sales.



biomerica.com

U.S. product sales have recently accounted for approximately 15% - 20% of Biomerica's total revenue. Asia and Europe account for the majority of the 80% - 85% of revenue that is generated overseas with a small contribution from the Middle East, South America and other international areas. Almost all of BMRA's revenue growth over the last two years has come from sales in Asia.

Non FDA-cleared Tests	FDA-cleared Tests
Allerquant™ IgG Food Intolerance ELISA Kit	ACTH ELISA Kit
Allerquant™ IgG Food Additives Kit	Calcitonin ELISA Kit
GAP™ IgM H. Pylori ELISA Kit	Erythropoietin ELISA Kit
GAP™ IgA H. Pylori ELISA Kit	GAP™ IgG H.Pylori ELISA Kit
Gliadin IgG ELISA Kit	hs-CRP ELISA
Gliadin IgA ELISA Kit	Myoglobin ELISA
Transglutaminase IgA ELISA Kit	PTH (Intact) ELISA Kit
Isletest™ GAD ELISA Kit	Troponin I ELISA
Isletest™ ICA ELISA Kit	AWARE™ Breast Self-Examination Kit
Isletest™ IAA ELISA Kit	Drugs-of-Abuse Rapid Tests
Intrinsic Factor Autoantibodies ELISA Kit	EZ Detect™ Fecal Occult Blood Test (OTC package)
LKM-1 Autoantibodies IgG ELISA Kit	EZ-HCG™ Rapid Pregnancy Test
Camplylobacter ELISA Kit	EZ-LH™ Rapid Ovulation Test
Cryptosporidium ELISA Kit	EZ Detect™ Fecal Occult Blood Test (Physician's package)
E. coli O157 ELISA Kit	
Giardia ELISA Kit	
Verotoxin ELISA Kit	
C. difficile Antibody ELISA Kit	
E. histolytica ELISA Kit	
TPMT ELISA Kit	
Fortel™ Cat Allergy Test	
Fortel™ Dog Allergy Test	
Fortel™ Microalbumin Test	
Fortel™ Ultra Midstream Pregnancy Test	
Fortel™ Ovulation Test	
EZ-PSA™ Rapid Test	
EZ-H. Pylori™ Rapid Test	
H. pylori Antigen Test	
Listeria Rapid Test	
Shigella Rapid Test	
Salmonella Rapid Test	

MARKET	
	Clinical Lab
	Physicians Office
	OTC

Sales / Distribution

The OTC products are sold under Biomerica's brand name in some of the largest chain retailers including Walgreen's. The professional POC products are sold through distributors which sell them to physician's offices/labs.

The clinical lab channel is serviced in the U.S. mostly through direct sales to reference labs and diagnostic companies. Outside the U.S. the clinical lab products are sold through third party distributors. Validation and selection of the "right" distributors in attractive demographic markets has proven to be successful for BMRA and has been a major catalyst behind the recent revenue growth in Asia. We expect that the company will continue to implement this strategy in other international markets including in Eastern Europe and South America.

MARKET

In vitro diagnostics encompass a huge portion of all professional and OTC medical testing and includes reagents, test kits, instrumentation and other testing devices, products, supplies and services. Biomerica's target markets and products are part of the IVD segment.

The worldwide market for IVD products is estimated at almost $60 billion and growing at about 10% annually. Kalorama Information, an independent research firm, estimated that growth of IVD has been even more robust outside the U.S., particularly in parts of Asia, Europe and Latin America (see chart below, from Kalorama Information). Similarly, Biomerica has recently experienced significant revenue growth in Asia.


Worldwide In Vitro Diagnostic Reagent Sales by Country/Region
2007-2012
(Sales $ MM)

	Sales 2007	%Mkt	Sales 2012	% Mkt	CAGR
N. America	$18,450	44	$23,090	41	5
EU 15/W. Europe	12,550	31	14,895	26	6
Japan	4,615	11	5,065	9	2
China	1,015	2	2,175	4	16
L. America*	830	2	1,695	3	15
India	520	1	1,000	2	14
E. Europe	710	1	950	2	9
ROW	4790	8	7446	13	9
Total	$41,950	100	$56,316	100	6

* includes Mexico

ELISA Remains Dominant in Clinical Lab Segment

Biomerica's clinical laboratory products consist of ELISA analytes and kits. ELISA diagnostics typically involves multi-well microtiter plates in which the wells of the plate are coated with a specific antigen. The plates are then filled with a patient sample (ie. - plasma, serum, etc) and the antibodies in the sample that are against the antigens will bind to the antigens. A detection antibody is then added which is covalently linked to an enzyme. Finally, an enzymatic substrate is added which interacts with the enzyme and generates visible color (read with the naked eye or an electronic plate reader) and indicates the quantity of antigen in the sample.



wikipedia.com

ELISA has been in existence for about 40 years and has had a long reputation for accuracy, performance and reproducibility. Other technologies have recently evolved such as molecular diagnostics that have shown improved sensitivity and potentially great promise in early detection of diseases such as cancer. Nonetheless, ELISA remains the dominant testing format in the clinical lab diagnostics space and is not likely to lose that designation anytime soon.

Dozens of companies compete in the ELISA space which includes manufacturers of reagents, kits, and instrumentation. Instrument manufacturers (which include major corporations such as Siemens, Roche, and Abbott among others) generally also supply their installed base with proprietary consumables which can provide a certain level of (capitve) customer loyalty and potentially bigger margins. Smaller players such as Biomerica which don't have the benefit of large R&D and marketing departments or feeding an installed base can effectively compete on product quality/consistency, product menu (including more esoteric tests which the major players may have little or no presence in), geographical diversification (particularly by exploiting ex-U.S. markets including emerging countries where the "majors" may have less of a competitive edge) and pricing as well as providing more intangible benefits such as superior customer service and prompt/reliable shipping.

According to data from Kalorama Information, the infectious disease assay category dominates in terms of share of the worldwide market for lab-based tests. The lab-based diagnostics experiencing the greatest growth over the last five years included glucose/HbA1C, autoimmune, cancer, infectious disease, and cardiac (see chart below, from Kalorama Information).

Worldwide Lab-Based Immunoassay Sales by Analyte Type 2007-2012 (ID, Tumor Markers, Cardiac Markers, Diabetes/HbA1c, Thyroid, Proteins, Autoimmune, Anemia, Therapeutic Drugs, Fertility, Allergy, Drugs of Abuse)


(Sales $ MM)

	IVD Sales 2007	% Mkt	IVD Sales 2012	% Mkt	CAGR
Infectious Diseases	2,500	37	3,325	37	6
Tumor markers	740	11	1125	13	9
Cardiac markers	785	12	1050	12	6
Diabetes/HbA1c	370	3	590	7	10
Thyroid	365	6	465	5	5
Proteins	330	5	420	5	5
Autoimmune	250	4	410	5	10
Anemia	305	5	390	4	5
Therapeutic Drugs	310	5	335	4	2
Fertility	280	5	330	4	3
Allergy	260	4	290	3	2
Drugs of Abuse	190	3	200	2	1
TOTAL	6,685	100	8,930	100	6

POC Growing On Improved Performance and Speed

The point-of-care market includes tests used by professionals such as at physician's offices and over-the-counter which are generally sold at retail (drug stores) and used directly by the consumer. Biomerica participates in both of these POC segments. Rapid, easy to use and interpret qualitative tests which are membrane-based test strips enclosed inside a plastic cassette are a big portion of the POC diagnostic market. Some more sophisticated testing is also approved for the POC setting and can include assay kits run on small (often handheld) analyzers. Common examples of POC test are pregnancy and insulin (diabetes) tests.

By most estimates the POC diagnostics market is expected to experience meaningful growth over the next several years. According to BCC Research the worldwide POC diagnostics market is expected to grow to approximately $16.5 billion by 2016 from $13.8 billion in 2011, representing a CAGR of 3.8%. However, excluding glucose (which accounts for ~90% of OTC POC, ~25% of professional POC, and ~65% of total POC) the global POC market is expected to grow at a CAGR of 7.2% (from $6.3 billion to $8.9 billion) over that same period. The anticipated major drivers of this expected growth are tests for cardiac markers, infectious diseases, and cancer.



Relative to the assays experiencing the highest rates of growth (ex glucose/HbA1C) in the two individual POC segments, Kalorama Information (see charts below) points to blood chemistry, critical care/cardiac markers, and cholesterol in the professional POC space and fecal occult blood, drugs of abuse, and lower volume products such as FSH (menopause), TSH (thyroid), and H.pylori (ulcers/stomach cancer) on the OTC segment. FSH and TSH

tests have had limited success in the U.S. but experienced much more rapid growth in international markets, particularly Europe.

OTC POC By Category

	Sales 2008	% Mkt	Sales 2013	% Mkt	% CAGR
OTC/Self Tests					
Glucose	$7,555	94	9,860	94	5
Pregnancy/Ovulation	390	5	450	4	3
Coagulation/PT	50	1	75	1	8
Fecal occult blood	25	0.3	40	0.4	10
Drugs of abuse	10	0.1	15	0.1	8
HbA1c	5	0.1	25	0.2	38
HIV	5	0.1	6	0.1	4
Cholesterol	5	0.1	6	0.1	4
Other	5	0.1	10	0.1	15
OTC/Self Total	**8,050**	**100**	**10,487**	**100**	**5**
OTC w/o glucose	495		627		5

Other = FSH, TSH, H. pylori, etc.

Professional POC By Category

Professional POC	2008	%	2013	%	CAGR
Glucose	1,334	28	1,400	24	1
Critical Care	500	10	700	12	7
Cardiac Markers	490	10	650	11	6
Infectious Diseases	470	10	550	9	3
Cholesterol/Lipids	335	7	475	8	7
Coagulation/PT, ACT	300	6	475	8	10
Hematology	290	6	310	5	1
HbA1c	200	4	325	5	10
Chemistry/Immunoassays	180	4	210	4	3
Fecal occult blood	155	3	200	3	5
Drugs of Abuse	155	3	185	3	4
Pregnancy	146	3	170	3	3
Urinalysis	120	3	140	2	3
Oncology	95	2	130	2	6
Other	10	0.2	15	0	8
Professional Total	**4,780**	**100**	**5,935**	**100**	**5**
Prof w/o glucose	3,446		4,535		6

Professional POC Growth

Driving much of this growth in the professional segment is healthcare providers shifting more testing from central labs to POC as the menu of CLIA waived tests increase. Higher healthcare costs, lower reimbursement rates, improved accuracy and the demand for and clinical advantages of immediate testing results will likely continue this trend indefinitely. POC testing offers certain significant advantages over central lab testing such as lower cost, simpler testing procedures, ease of interpretation, improved therapeutic intervention and the elimination of the need for patients to return for a follow-up visit. While these have always been benefits of POC testing, in the past clinical lab testing had benefitted from greater sensitivity and specificity which had deterred a greater reliance on POC diagnostics. The recent advent of new technologies has significantly narrowed the gap between the quality of results delivered from the professional labs versus POC which has been a major impetus for the macro shift towards a greater use of POC diagnostics.

Another recent driver of interest in POC testing which primarily addresses the professional POC segment (although also has relevance to OTC POC) is political/legislative/reimbursement/advocacy efforts which are focused on lowering healthcare costs through earlier diagnosis and intervention. Examples include Obamacare which has a focus on quality over quantity of care and increasing the insured base by 30+ million, improved reimbursement, and recent recommendations by the U.S. Preventative Services Task Force (USPSTF) and/or Centers for Disease Control relative to advocating increased or improved testing/screening for conditions such as HIV, HCV, prostate cancer, and breast cancer.

OTC POC Growth

Growth in the OTC setting is coming from a combination of catalysts including an increasing breadth of tests for more indications, more user friendly tests (such as Biomerica's fecal occult blood test), more accurate/sensitive tests, DTC marketing campaigns, and the aforementioned recent focus on reducing healthcare costs through earlier diagnosis.

U.S. Dominates POC Testing, Although Overseas May Offer Higher Growth…

According to estimates by Kalorama Information (chart below), the U.S. accounts for approximately 55% of the worldwide market for POC diagnostics with Europe next inline at 35%. The majority of growth in POC may come from overseas, however.

Region	Sales ($MM)	Percent of Market
United States	$7,100	55%
Europe	4,500	35%
Asia/Japan	647	5%
Rest of World	647	5%
Total	**12,894**	**100%**

In Europe, where POC testing had been restricted to some degree as central lab testing dominated in certain countries such as Germany, a shift is underway as a result of a greater emphasis on earlier diagnosis and prevention - which should benefit the POC setting. Similarly, the U.K. recently adopted a more decentralized approach to disease prevention and healthcare delivery, largely driven by an emphasis on controlling healthcare costs - this has resulted in greater use of POC testing. Japan's highly centralized healthcare system means most testing is performed in clinical labs. The Japanese POC market is loosening however, particularly for rapid tests for emergency and critical care. Other parts of Asia, including China and India, which are evolving economically as well as adopting a more Western diet (i.e. - high fat/calorie/cholesterol) are viewed as huge growth opportunities for U.S. diagnostics companies - higher incomes means POC tests are now more affordable in these countries and poorer diets means an increased need for testing of a variety of conditions (cancer, cholesterol, cardiac markers, etc). In Africa and other emerging markets viral infections including HIV and hepatitis C continue to be problematic and even of epidemic proportions in certain areas (e.g. - HIV in sub-Saharan Africa) - rapid POC testing has quickly become a front-line measure to help control the further spread of these diseases.

FINANCIAL CONDITION / CAPITAL STRUCTURE

Balance Sheet / Cash Flow

Biomerica has a history of maintaining a healthy financial condition and remains that way currently. Cash balance at the end of fiscal 2013 (ending 5/31/2013) was $2.5 million. BMRA has access to a credit line but has nothing drawn on it. Book value stands at $5.8 million and quality of assets appears reasonably strong. Intangibles account for less than 5% of total assets.

Biomerica is generating positive cash flow on both a cash from operations as well as a free cash flow basis (cash from operations less CapEx). Through fiscal 2013 cash flow from operations and free cash flow were $1.4 million and $1.1 million, respectively.

Assuming BMRA continues to generate positive cash flow, book value should continue to increase. BMRA's ability to generate positive cash flow is due in no small part to their relatively meager CapEx needs and SG&A spend along with keeping manufacturing costs down (low cost facility in Mexico), exiting most R&D functions, and low overhead. We do not anticipate any significant PP&E/intangible asset purchases in the foreseeable future. Relative to SG&A we note that executive compensation is relatively meager (see table below from BMRA public filings) and is possibly the lowest of any company we cover in the med-tech space (many of which, unlike BMRA, do not generate positive cash flow). We think this speaks loudly to management's and the board's focus on increasing shareholder value.

EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE (Yrs ended May 31, 2011 & 2012)

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($) (4)	Non Equity Incentive Plan Compen-sation ($)	Non-qualified Deferred Compen-sation Earnings	All Other Compen-sation ($)	Total ($)
Zackary Irani Chairman & Chief Executive Officer	2012	135,000	8,050	-0-	16,784	-0-	-0-	-0-	**159,834(1)**
	2011	106,250	-0-	-0-	15,345	-0-	-0-	-0-	**121,595(1)**
Francis Capitanio President	2012	135,063	8,050	-0-	11,189	-0-	-0-	-0-	**154,302(2)**
	2011	133,835	-0-	-0-	9,206	-0-	-0-	-0-	**143,041(2)**
Janet Moore Chief Financial Officer, Treasurer & Secretary	2012	95,832	8,050	-0-	7,609	-0-	-0-	-0-	**111,491(3)**
	2011	89,500	-0-	-0-	10,741	-0-	-0-	-0-	**100,214(3)**

Capital Structure

BMRA's capital structure is straightforward with no debt, no preferred, no convertibles or esoteric securities. Basic and dilutive share counts are 7.0 million and 7.5 million, respectively, which are impressively minimal and relatively very low compared to most micro-cap companies that we cover. Unlike many companies which struggle to maintain solvency and resort to regular and sizeable share compensation programs in an effort to reduce cash burn, BMRA funds itself with internally generated funds and does not have to rely on issuance of dilutive stock/options/warrants to maintain operations. We think this again speaks to BMRA's leadership and attention to increasing shareholder value.

OUTLOOK

Revenue: *Asia Remains Near-Term Catalyst. Near-to-Mid Term We Look For Europe to Return to Growth, Deeper Penetration Into S. America and Double-Digit Growth in U.S.*

We think Asia continues to be the major catalyst driving near-term revenue growth as Biomerica expands both their geographic reach as well as their product menu throughout the continent, both key aspects to the company's growth strategy, particularly overseas. With Asia accounting for over 60% of the world's population and experiencing increasing demand for higher quality healthcare as a result of greater economic prosperity, an aging population (particularly in China due to their high birth rate after 1949 and one-child policy), and greater adoption of Western diets, Asia represents an under-served market with potentially very attractive opportunities for the foreseeable future.

Similar to Asia, parts of South America have benefitted from rapid economic growth and a resultant increased demand for better healthcare including earlier diagnosis and intervention. While Biomerica's revenue from South America has been minimal to-date, we expect the company will look to expand their presence there through additional distribution agreements and think over the mid-to-long term South America could be a meaningful contributor to revenue.

Europe accounts for ~35% of BMRA's revenue. Growth had recently flattened but significantly increased in fiscal Q4 2013 with management pointing to increased sales of products not purchased previously in Europe as the catalyst. It is not clear whether this catalyst will continue to buoy growth in Europe. While the regulatory environment is significantly less stringent in most of Europe as compared to the U.S. relative to diagnostic tests, POC testing there is still largely in its infancy. The recent shift in greater (although still very modest) reliance on POC testing in some parts of Europe including Germany and the U.K. as a result of more emphasis on earlier diagnosis and prevention should offer greater opportunities for growth of both BMRA's POC and clinical lab products. In addition, Eastern Europe, which is more of an emerging territory with potentially less competition could provide opportunity for growth via bolt-on distribution. We think Europe can return to growth over the next couple of years and model somewhat modest mid-to-single digit revenue growth in Europe from fiscal 2014 through 2016 - which actually could end up being conservative.

In contrast to BMRA's international markets, growth in the U.S. has less to do with expanding distribution or their overall product portfolio and more to do with exploiting niche areas and potentially bringing some of their professional POC products to the OTC/retail channel and/or seeking CLIA waiver for some of their ASR tests (both of which would require additional regulatory approval). Product differentiation such as their more user friendly fecal occult blood test as well as offering a menu of more esoteric tests provides somewhat of a competitive barrier against their much larger and deeper entrenched peers. We expect this to continue to be a part of BMRA's domestic strategy. If the company can bring more of their existing tests to the POC channel, which is already a well-established part of the U.S. healthcare system, that could provide a real opportunity to grow domestic revenue. Another real opportunity for U.S. growth could be with potential partnerships or licensing agreements to supply ASR or CLIA-waived test kits to instrument manufacturers. Instrument manufacturers have a real interest expanding their testing menus as the more tests that can be run on each instrument can provide a significant competitive advantage - BMRA's more esoteric tests potentially offer valuable competitive differentiation.

Operating Expenses: *Should Be Highly Leverageble - We Look for Operating Income to Grow Faster than Revenue*

As we have detailed in our coverage of BMRA, the company's operating expenses as a % of revenue have historically been relatively low and have even improved consistently with the recent revenue growth. Based on our discussions with management we think it's likely that BMRA may squeeze even more leverage in operating expenses with further revenue growth. Gross margin has also widened with growth in sales (although GM contracted in the last two quarters with a dip in sales) - which we also think can continue to benefit as revenue grows and dilutes the fixed-cost portion of COGS. Our financial model assumes GM widens about 500 basis points (37.5% - 42.5%) from 2013 to 2017 and operating expenses as % of revenue fall from 29.6% to 22.8% over that same period on annual revenue growth of 17%. Both our modeled revenue growth and expense leverage could be considered highly conservative given BMRA's recent historical performance - we will update our forecasts if and when appropriate. Assuming our numbers turn out fairly accurate, we think operating income could jump over 67% in 2014 on 11% revenue growth and increase at an annual rate of 40% from 2014 through 2017 on revenue growth of 19% over that same period. If our numbers turn out conservative, BMRA's operating income could accelerate even more rapidly than what we currently model.

EPS: *Expect Consistent Growth*

The combination of revenue growth, incremental widening of GM and increased operating leverage should result in consistent EPS growth, although perhaps not as rapidly as growth of operating income as BMRA's NOLs and deferred tax assets will expire and result in an increase in the effective income tax. Nonetheless, EPS should still show strong growth. We model EPS to grow from $0.07 in 2013 to $0.11 in 2014 and to $0.19 in 2017. We repeat however, that our revenue and expense estimates could be conservative and if that ends up being the case, so likely will our EPS estimates.

VALUATION / RECOMMENDATION

We use a comparable cohort of seven companies of various market capitalizations in the medical diagnostics space with products/services that target the POC and/or clinical lab markets to value BMRA. Based on several metrics, BMRA is valued between $1.86 and $2.82 per share. Average is $2.29 which we round up to $2.50/share.

Relative to risk mitigation, cash flow and book value are key. BMRA's current enterprise value is less than 5.5x EBITDA (compared to 18x comp avg) and market value is just 1.1x book value (compared to 3.2x comp avg). Biomerica is generating positive free cash flow (meaning book value should increase further), has liquid and high quality assets ($2.5 million cash, high quality A/R and inventory, minimal intangibles), and zero debt. We think all this adds up to very low downside risk.

In summary, we believe BMRA is significantly undervalued with some of the lowest downside risk available in the micro-cap space. We recommend buying the shares up to our $2.50/share target price and are maintaining our Outperform rating.

Comparable Multiples

Ticker	P/E (ttm)	P/E (FY1)	P/E (FY4)	P/Book	EV / EBITDA (ttm)	P/S (ttm)	P/S (FY1)
TRIB	25.7	18.0	13.1	2.4	19.0	5.0	4.5
CEMI	32.8	45.1	9.0	1.8	11.0	1.3	1.2
VIVO	25.4	22.3	15.3	6.3	15.1	5.2	5.0
LIFE	30.9	16.4	16.6	2.7	12.4	3.4	3.4
ERB	N/A	N/A	N/A	2.1	0.0	1.6	N/A
CONX	N/A	N/A	N/A	1.9	N/A	1.0	0.9
ABAX	31.7	31.6	21.0	4.9	26.7	4.7	4.4
Average	**29.3**	**25.7**	**13.9**	**3.2**	**18.3**	**3.2**	**3.2**

FY1, FY4 = forecast year 1, forecast year 4

Biomerica Stock Value Based On Comp:

	P/E (ttm)	P/E (FY1)	P/E (FY4)	P/Book	EV / EBITDA (ttm)	P/S (ttm)	P/S (FY1)	AVG
BMRA	$2.26	$1.86	$2.15	$2.33	$1.99	$2.61	$2.82	**$2.29**

FINANCIAL MODEL

Biomerica Inc.

	2013 A	Q1E	Q2E	Q3E	Q4E	2014 E	2015 E	2016 E	2017 E
Total Revenues	$6,473.0	$1,434.5	$1,768.5	$1,926.5	$2,022.7	$7,152.2	$8,631.7	$10,135.4	$11,912.7
YOY Growth	*6.4%*	*-15.7%*	*-6.1%*	*36.0%*	*37.6%*	*10.5%*	*20.7%*	*17.4%*	*17.5%*
Cost of Goods Sold	$4,045.1	$972.6	$1,147.8	$1,165.5	$1,152.9	$4,438.8	$5,144.5	$5,898.8	$6,849.8
Gross Income	$2,427.9	$461.9	$620.7	$761.0	$869.7	$2,713.4	$3,487.2	$4,236.6	$5,062.9
Gross Margin	*37.5%*	*32.2%*	*35.1%*	*39.5%*	*43.0%*	*37.9%*	*40.4%*	*41.8%*	*42.5%*
SG&A	$1,454.8	$329.9	$357.2	$368.0	$380.3	$1,435.4	$1,700.5	$1,925.7	$2,239.6
% SG&A	*22.5%*	*23.0%*	*20.2%*	*19.1%*	*18.8%*	*20.1%*	*19.7%*	*19.0%*	*18.8%*
R&D	$459.1	$105.0	$105.0	$105.0	$105.0	$420.0	$438.0	$452.0	$477.0
% R&D	*7.1%*	*7.3%*	*5.9%*	*5.5%*	*5.2%*	*5.9%*	*5.1%*	*4.5%*	*4.0%*
Operating Income	$514.0	$27.0	$158.5	$288.0	$384.5	$858.0	$1,348.8	$1,858.9	$2,346.3
Operating Margin	*7.9%*	*1.9%*	*9.0%*	*14.9%*	*19.0%*	*12.0%*	*15.6%*	*18.3%*	*19.7%*
Total Other Income (Expense)	$10.5	$1.5	$1.5	$1.5	$1.5	$6.0	$7.4	$9.1	$14.2
Pre-Tax Income	$524.5	$28.5	$160.0	$289.5	$386.0	$864.0	$1,356.2	$1,868.0	$2,360.5
Tax expense (benefit)	($12.5)	$0.0	$0.0	$0.0	$0.0	$0.0	$169.5	$560.4	$708.2
Tax Rate	*-2.4%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*12.5%*	*30.0%*	*30.0%*
Net Income	$537.0	$28.5	$160.0	$289.5	$386.0	$864.0	$1,186.6	$1,307.6	$1,652.4
YOY Growth	*-2.1%*	*-94.8%*	*-45.1%*	*22.1%*	*-1183.4%*	*1148.4%*	*37.3%*	*10.2%*	*26.4%*
Net Margin	*8.3%*	*2.0%*	*9.0%*	*15.0%*	*19.1%*	*12.1%*	*13.7%*	*12.9%*	*13.9%*
EPS	$0.07	$0.00	$0.02	$0.04	$0.05	$0.11	$0.14	$0.15	$0.19
YOY Growth	*-6.6%*					*966.8%*	*36.7%*	*6.8%*	*25.8%*
Diluted Shares O/S	7,451	8,150	8,160	8,170	8,170	8,163	8,200	8,460	8,500

Brian Marckx, CFA

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

LEADERSHIP

Zackary Irani
CEO and Chairman
Mr. Zackary Irani has been a Director of the Company, and has been serving as the Company's Chairman of the Board and Chief Executive Officer since April 29, 1997. Prior to that time, Mr. Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During fiscal 2008 and 2009, Mr. Irani also served as Chairman of the Board of Lancer Orthodontics, Inc. and served as Lancer's Chief Executive Officer from April 1997 until April 2004.

Janet Moore
CEO and Director
Ms. Janet Moore has been a Director of the Company since April 29, 1997, and has been serving as the Company's Secretary and Treasurer since 1985. She has served as the Company's Chief Financial Officer since 1999 and has been an employee of the Company since 1976. During fiscal 2008 and through September 29, 2008, Ms. Moore also served as a director and Secretary of Lancer Orthodontics, Inc.

Francis Capitanio
President
Mr. Francis Capitanio, age 68, has served as the President of the diagnostics division of Biomerica since July 10, 2000. Mr. Capitanio was President and Chief Executive Officer of Kalisto Biologicals, Inc. from 1997 until 2000. From 1980 until 1996, he was President and Chief Executive Officer of Diatech Diagnostics.

Francis R. Cano
Director
Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. Dr. Cano is the managing director of Cano Biotechnology, a thirteen year old consulting business which is focused on vaccines and immunotherapeutics. He co-founded Aviron in 1993 and served as the President and Chief Operating Officer. The Company developed an intranasal flu vaccine and was acquired by MedImmune in 2002 for $1.2 billion. From 1972-1993 Dr. Cano held various scientific/management positions with American Cyanamid, the last of which was as Vice President-General Manager of the Lederle-Praxis Biological Division. During fiscal 2008 and through September 29, 2008, Dr. Cano also served on the board of Lancer Orthodontics, Inc., and currently serves on the board of Arbor Vita Corporation and Dynavax.

Allen Barbieri
Director
Mr. Allen Barbieri has served as a Director of the Company since October 1999. Mr. Barbieri currently serves as the CEO of LubriGreen Biosynthetics, a privately held renewable lubricants manufacturing company. Prior to that, from April 2004 to Sept. 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc. and from 1999 until the present time, Mr. Barbieri has also worked as a private investor. From 1998 to 1999, he served as President and Chief Financial Officer of Buy.com. From 1994 until 1998 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank.

Jane Emerson
Director
Dr. Emerson has served as a director of the Company since April 2007. Since July 1, 2009 Dr. Emerson has served as Chief of Clinical Pathology at the USC Keck School of Medicine, Los Angeles, California. From 1994 to 2009 Dr. Emerson served as Chief, Division of Clinical Pathology for the University of California, Irvine. From 2000 to 2009 she also served as the Chief of Clinical Pathology and from 2004 to 2009 as a Clinical Professor for the University of California, Irvine. From 2005 to 2009 Dr. Emerson served as Vice Chair for Clinical Programs, Department of Pathology and Laboratory Medicine for the University of California, Irvine.

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Investment Research ("ZIR"), Zacks & Company (ZCO") and Zacks Small-Cap Research ("Zacks SCR") and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned.

ZCO and Zacks SCR are separate legal entities. ZCO is U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corp. This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments through ZCO.

Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution of Zacks Ratings is as follows on the 1028 companies covered: Buy/Outperform- 14.9%, Hold/Neutral- 78.0%, Sell/Underperform – 6.0%. Data is as of midnight on the business day immediately prior to this publication.